Technical Analysis for FENC - Fennec Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade F 3.96 -2.22% -0.09
FENC closed down 2.22 percent on Monday, May 20, 2019, on 43 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical FENC trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
BB Squeeze Ended Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
180 Bearish Setup Bearish Swing Setup -2.22%
Bollinger Band Squeeze Range Contraction -2.22%
BB Squeeze + Lower Band Touch Range Contraction -2.22%

Older signals for FENC ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Fennec Pharmaceuticals Inc., formerly Adherex Technologies Inc., is a biopharmaceutical company focused on cancer therapeutics. The Company's lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. STS has been studied by cooperative groups in over two Phase III clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. The Children's Oncology Group (COG) ACCL0431 protocol enrolled 20% childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.
Biopharmaceutical Cancer Disease Oncology Brain Tumor Cancer Therapeutics Neuroblastoma Osteosarcoma Hearing Loss Localized Tumors Neoplasms
Is FENC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 12.51
52 Week Low 3.91
Average Volume 77,418
200-Day Moving Average 6.8712
50-Day Moving Average 4.8398
20-Day Moving Average 4.3325
10-Day Moving Average 4.187
Average True Range 0.2672
ADX 12.93
+DI 14.5726
-DI 18.8882
Chandelier Exit (Long, 3 ATRs ) 4.0784
Chandelier Exit (Short, 3 ATRs ) 4.7116
Upper Bollinger Band 4.6935
Lower Bollinger Band 3.9715
Percent B (%b) -0.02
BandWidth 16.664743
MACD Line -0.2276
MACD Signal Line -0.2365
MACD Histogram 0.0089
Fundamentals Value
Market Cap 62.43 Million
Num Shares 15.8 Million
EPS -0.29
Price-to-Earnings (P/E) Ratio -13.66
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.10
Resistance 3 (R3) 4.10 4.07 4.07
Resistance 2 (R2) 4.07 4.03 4.06 4.06
Resistance 1 (R1) 4.01 4.01 4.00 4.01 4.06
Pivot Point 3.98 3.98 3.97 3.97 3.98
Support 1 (S1) 3.92 3.94 3.91 3.92 3.86
Support 2 (S2) 3.89 3.92 3.88 3.86
Support 3 (S3) 3.83 3.89 3.85
Support 4 (S4) 3.83